INSM
Insmed Incorporated
NASDAQ · USHealthcareBiotechnology
$107.02-1.20%
Price as of Jul 20, 2026
INSM growth
Insmed Incorporated growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +115.1%
- EBITDA
- -17.8%
- EBIT
- -15.1%
- EPS
- +3.4%
- Free cash flow
- -20.6%
- Operating cash flow
- -17.6%
Forward estimates
- Revenue
- +152.2%
- EBITDA
- -91.2%
- EPS
- +77.6%
Three-year CAGR
- Revenue
- +35.2%
- EBITDA
- -43.1%
- EBIT
- -34.0%
- Net income
- -39.7%
- EPS
- -15.1%
- Free cash flow
- -37.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.